Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore™ for COVID-19 Available to its Network of Healthcare Provider Partners
Aditx Therapeutics (ADTX) announced a partnership with Meridian Health Services Network to offer AditxtScore for COVID-19, a service that monitors immunity through a comprehensive immune profile. This service allows clients, including major national organizations, to better track their employees' immune responses and increase workplace safety. AditxtScore assesses specific immune biomarkers to provide insights on protection against COVID-19, complementing existing vaccination efforts. The company is seeking 510(K) marketing authorization, and AditxtScore is currently not FDA cleared.
- Partnership with Meridian Health Services Network expands distribution of AditxtScore for COVID-19.
- AditxtScore for COVID-19 offers detailed insights into immune responses, aiding clients in employee health management.
- Potential for increased demand as businesses seek comprehensive solutions for COVID-19 immunity monitoring.
- AditxtScore is not yet FDA cleared, which may limit its market acceptance.
- Dependence on regulatory approval can introduce uncertainty for timelines and potential revenues.
MOUNTAIN VIEW, Calif., May 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Meridian Health Services Network (Meridian HSN) will offer AditxtScore™ for COVID-19 to its network of healthcare provider partners.
Aditxt is pioneering the development of a new technology platform that provides a personalized, comprehensive profile of the immune system. By assessing an individual's immune biomarkers, AditxtScore will be able to measure indications of immunity to specific disease. AditxtScore applications include the recently commercialized AditxtScore for COVID-19, developed for use in detecting antibodies and neutralizing antibodies against SARS-CoV-2 antigens. Other applications under development include, among others, predicting dynamic monitoring of the immune system in infectious and autoimmune diseases, organ transplantation, gut health, and allergy.
"While COVID-19 vaccines will be critical tools for an end to the pandemic, monitoring the immune system's response is key to understanding a person's level of protective immunity," said Amro Albanna, co-founder and CEO of Aditxt. "Key stakeholders will need to adapt to emerging data and new variants both in the US and around the world, and the AditxtScore platform potentially represents an important complement. We are thrilled to add Meridian HSN to our growing AditxtScore Channel Partner network with an opportunity to support its clients, including national hotel chains, aviation and hospital networks."
AditxtScore for COVID-19 will be included in Meridian HSN's Mobile COVID-19 Antibody testing and telemedicine services to offer a more robust point of care health option to meet their employees' healthcare needs. As an AditxtScore Channel Partner, Meridian HSN employer clients will have the ability to track the immune response of their employees to provide a safer environment as people return to work.
David Bloom, CEO of Meridian Health Services Network, said, "Our goal is to provide the most robust COVID-19 testing services to our partners to ensure every employee and their families can access the proper care to protect themselves. Aditxt's innovative immune monitoring technology provides a comprehensive look at an individual's protective immunity against COVID-19 and we're pleased to add it to our roster of health tests for our clients."
About Aditxt Score for COVID-19
AditxtScore for COVID-19 platform provides an informative and comprehensive profile of the immune response to COVID-19 and related treatment and vaccines in a single test, rather than relying on multiple tests. The platform identifies and measures specific cellular responses, including T cell activation, cytokine production and B cell receptors, to determine long-lasting immunity following natural infection or vaccination. Generalized population levels that track the total number vaccinated may not provide an accurate safeguard against the spread of the virus. AditxtScore for COVID-19 focuses on a patient's immunity on whether they are protected from infection to help them make informed health decisions including travel, participate in group gatherings or return to work. Aditxt is seeking 510(K) marketing authorization from AditxtScore. Currently AditxtSocre is not FDA cleared but specimens are processed at Aditxt's CLIA-certified AditxtScore Center.
For more information on AditxtScore and how it can bolster COVID-19 testing efforts, visit aditxtscore.com
About Aditx Therapeutics
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
About Meridian Health Services Network
Meridian Health Services Network's mission for over 20 years is to create lasting and impactful healthcare solutions for our clients. These range from health and wellness, on-site services to healthcare financial funding. For additional information/news inquiries, please visit www.meridianhsn.com or reach out directly at 1.800.994.1143.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aditxt-signs-channel-partner-agreement-with-meridian-hsn-to-make-aditxtscore-for-covid-19-available-to-its-network-of-healthcare-provider-partners-301285399.html
SOURCE Aditx Therapeutics
FAQ
What is Aditxt's recent partnership announcement about?
What is AditxtScore for COVID-19?
When was the press release for Aditxt's partnership issued?
What is the stock symbol for Aditxt Therapeutics?
What does AditxtScore help employers with?
